Full Length Research Paper

Anticonvulsant activities of friedelan-3-one and n-dotriacontane both isolated from *Harungana madagascariensis* Lam (Hypericaceae) seeds extracts

Jordan Kache Signe¹, Godfred Ayimele Aponglen¹*, James Mbah Ajeck¹ and Germain Sotoing Taiwe²

¹Department of Chemistry, Faculty of Science, University of Buea, Box 63-Buea, Cameroon.
²Department of Zoology, Faculty of Science, University of Buea, Box 63-Buea, Cameroon.

Chemical investigation of the crude methanol/methylene chloride (1:1) extract of the seeds of *Harungana madagascariensis* resulted in the isolation of two known compounds namely n-dotriacontane and friedelan-3-one. The structures of the isolated compounds were determined on the basis of 1D NMR spectroscopy and comparison with literature data. The crude extract and the two compounds were evaluated for their anticonvulsant effects on pentylenetetrazole or picrotoxin induced convulsions in mice. All the tested treatments showed anticonvulsant effects on experimental models of epileptic seizures chemically induced in mice. Friedelan-3-one and the crude extract showed up to 83% protection of animals against convulsions while n-dotriacontane produced a maximum of 33% protection.

**Key words:** *Harungana madagascariensis* extracts, friedelan-3-one, n-dotriacontane, anticonvulsant activity.

INTRODUCTION

Plants are an important source of novel molecules for the development of new antiepileptic agents to solve the problems of toxicity, side effects, and ineffectiveness in the control of epilepsy (Hui-Ling et al., 2014). Though there is limited literature on pure components in herbal medicines that have been reported to treat neurological disorders, many kinds of herbs have been used to treat epilepsy.

In fact, this affects up to 50 million people (Wagner, 2016) of all age groups, sex and social class worldwide (Nirupam et al., 2012) with 2 million new cases every year including 75% from low- and medium-income countries (LMICs) (Wagner, 2016). In addition to this, with the emergence of numerous adverse outcomes and pharmaco-resistance to the available antiepileptic drugs (AEDs) (Wahab, 2010; Nirupam et al., 2012), there is an urgent need for the development of new AEDs with the ultimate aim of achieving complete freedom from seizures with improved tolerance in all patients. We therefore decided to investigate the anticonvulsant potentials of the crude extract of the seeds of *H. madagascariensis* and compounds isolated from it. This with year including 75% from low- and medium-income countries (LMICs) (Wagner, 2016). In addition to this, with the emergence of numerous adverse outcomes and pharmaco-resistance to the available antiepileptic drugs (AEDs) (Wahab, 2010; Nirupam et al., 2012), there is an urgent need for the development of new AEDs with the ultimate aim of achieving complete freedom from seizures with improved tolerance in all patients. We therefore decided to investigate the anticonvulsant potentials of the crude extract of the seeds of *H. madagascariensis* and compounds isolated from it.
the hope of obtaining novel leads that could be further developed to obtain new, safe and efficacious antiepileptic agents.

MATERIALS AND METHODS

General

Extraction, purification and phytochemical analyses were carried out in the Natural Product Laboratory, Department of Chemistry, Faculty of Science, University of Buea. Samples were weighed on an ohaus electronic and scale balance. Column chromatography was carried out using Merck silica gel 60 (particle size 60-200 μm). For thin layer chromatographic (TLC) analysis, precoated aluminium sheets with silica gel (Alugramsil/UV 254) were used. Zones on these plates were visualized under UVGL-58 lamp at 254/365 nm. Alternatively, the plates were exposed to iodine vapour in an iodine chamber. Melting points were recorded on Meltemp II apparatus and are uncorrected. 1H and 13C NMR spectroscopy was carried out in a Utah State University, USA. 13C NMR (75 MHz-CDCl3) and 1H NMR (300 MHz-CDCl3) spectra were recorded on variant mercury Vx-300 MHz machine. The chemical shift values were quoted in parts per million (ppm) on the scale, with tetramethylsilane (TMS) as internal standard. NMR spectra were obtained with deuterated chloroform (CDCl3).

Biological screening was carried out in the collaborating Zoology and Animal Physiology Laboratories of the Department of Zoology and Animal Physiology, Faculty of Science, University of Buea. Albino Swiss mice of either sex (18-22 g) were obtained from the Animal Centre, University of Buea, Cameroon and were kept in plastic cages at room temperature. They were fed with balanced rodent pellet diet and water ad libitum and were acclimatized for one week before using them for experiments. The procedures used in the study were in compliance with the ethical guidelines of the University of Buea and National Institutes of Health guide for the Care and Use of Laboratory Animals for experimental investigations. The following drugs were used: picrotoxin (Sigma-Aldrich, St. Louis, USA), pentylenetetrazole, PTZ (Sigma-Aldrich, St. Louis, USA), Clonazepam, CLZ (Roche, France).

Plant material

The seeds of *H. madagascariensis* were collected in Awing, Northwest region of Cameroon in February 2018. The plant was identified by Mr. Elias Ndive and a voucher specimen of it, No. SCA4408 is deposited at the Limbe Botanic Garden, Cameroon.

Extraction, isolation and identification of compounds

The seeds of *H. Madagascariensis* were air-dried then ground into coarse powder. The powder (1.9 kg) was macerated at room temperature with CH2Cl2/MeOH (1:1) (3 × 3 days each). The filtrate was then concentrated to dryness using a rotavapor to yield 227 g of crude extract. The extract was stored at 4°C. The crude extract was subjected to open column chromatography with silica gel as adsorbent. Elution was performed with hexane/ethyl acetate and ethyl acetate/methanol in increasing polarity. A total of 135 fractions (250 ml each) were collected, concentrated in vacuo in a rotator evaporator and their compound profiles monitored by using analytical TLC plates. Following the analytical TLC, the eluents were regrouped into 6 main fractions indexed A - F. AHM1 (n-dotriacontane, 60 mg) crystallized as a white solid (in acetone) from Fractions 1 - 7 (Fraction A) that was obtained with pure hexane from the main column. It had a melting point of 68-70°C and an Rf of 0.5 (pure hexane). Repeated column chromatography of Fraction B (Fractions 8-20 obtained with 5% EtOAc/Hex from the main column) afforded a white solid (300 mg) in acetone coded AHM2; with a melting point of 248-250°C and an Rf of 0.4 (2% EtOAc/Hex).

Antiepileptic assay

Picrotoxin (PCT)-induced convulsion test

Mice were divided into fourteen groups of six mice each, and received the crude extracts: AHM (5, 10, 15 and 20 mg/kg; i.p.), AHM1 (5, 10, 15 and 20 mg/kg; i.p.), AHM2 (5, 10, 15 and 20 mg/kg; i.p.), clonazepam (1 mg/kg, i.p.) or vehicle (10 mL/kg p.o. One hour later, tonic-clonic seizures were induced in mice by intraperitoneal (i.p) injection of 7.5 mg/kg PCT. The mice were observed for 15 min and the protective effects of the different treatments were recorded. Animals that did not convulse within the 15 min of observation were qualified as protected (Bum et al., 2001).

Pentylenetetrazole (PTZ)-induced convulsion test

Fourteen groups of six mice were treated as discussed previously. However, the positive control group received 0.1 mg/kg clonazepam i.p. Tonic-clonic seizures were induced in mice by the i.p. injection of 70 mg/kg PTZ. The protective effect of the different treatments given 1 h before PTZ injection was recorded. Animals that did not convulse within the 10 min of observation were qualified as protected (Bum et al., 2011).

Statistical analysis

The data were expressed as mean ± S.E.M. The data were analyzed with Graph Pad Prism Software version 4.03. Statistical analysis of data was done by One-way ANOVA, followed by Dunn’s post-hoc test. A level of p < 0.05 was considered as statistically significant (Umukoro et al., 2013).

RESULTS

Identification of the AHM1 and AHM2

The structures of the compounds (Figure 1) were determined by analysis of their NMR data and comparison with those reported in literature. The 1H NMR of AHM1 showed two signals; a triplet at about 0.88 ppm (1H) and a broad signal at about 1.26 ppm (31H). Comparison of its 1H NMR spectral data with the published data for n-dotriacontane; a long straight chain alkane with 32 carbons was thus identified as compound AHM1 in the crude extract. Fourteen groups of six mice were treated as discussed previously. However, the positive control group received 0.1 mg/kg clonazepam i.p. Tonic-clonic seizures were induced in mice by the i.p. injection of 70 mg/kg PTZ. The protective effect of the different treatments given 1 h before PTZ injection was recorded. Animals that did not convulse within the 10 min of observation were qualified as protected (Bum et al., 2011).

Statistical analysis

The data were expressed as mean ± S.E.M. The data were analyzed with Graph Pad Prism Software version 4.03. Statistical analysis of data was done by One-way ANOVA, followed by Dunn’s post-hoc test. A level of p < 0.05 was considered as statistically significant (Umukoro et al., 2013).
6.80, 14.6, 17.9, 20.2, 18.6, 32.1, 35.0 and 31.8 ppm indicated the presence of methyl carbons C-23, C-24, C-25, C-26, C-27, C-28, C-29 and C-30 respectively. Those at 22.3, 41.5, 41.3, 18.2, 35.6, 30.5, 32.4, 36.0, 35.3, 32.8 and 39.2 ppm revealed the presence of methylene carbons C-1, C-2, C-6, C-7, C-11, C-12, C-15, C-16, C-19, C-21 and C-22 respectively. The signals at 58.2, 53.1, 59.5 and 42.8 ppm indicated the presence of methyne carbons C-4, C-8, C-10 and C-18 respectively. Finally, the signals at 42.1, 37.4, 39.7, 38.5, 30.0 and 28.2 ppm indicated the presence of the quaternary carbons C-5, C-9, C-13, C-14, C-17 and C-20 respectively. Comparison of the NMR spectral features of AHM2 with existing literature for friedelan-3-one previously isolated from *Terminalia avicennioides* (Abdullahi et al., 2011) shows that AHM2 is friedelan-3-one; a pentacyclic triterpene.

**Anticonvulsant activity**

The anticonvulsant effects of the MeOH/CH<sub>2</sub>Cl<sub>2</sub> crude extract (AHM), n-dotriacontane (AHM1), and friedelan-3-one (AHM2) (5, 10, 15 and 20 mg/kg each) were assessed based on their abilities to prevent, or delay the onset of tonic-clonic seizures (convulsions) induced by pentylenetetrazole (PTZ) and picrotoxin (PCT), both chemoconvulsant agents (70 and 7.5 mg/kg respectively) in mice (Bum et al., 2001).

**Effect of AHM on PTZ-induced convulsion**

The effects of intraperitoneal (i.p) injection of AHM (5-20 mg/kg) on convulsions induced by PTZ (70 mg/kg, i.p) in mice are shown in Table 1 and Figure 2. AHM (5-20 mg/kg) protected 33.33-83.33% of mice against convulsions induced by PTZ while the reference drug, clonazepam (0.1 mg/kg) offered 100% protection against convulsions, as none of the animals exhibited tonic-clonic seizures induced by PTZ in mice. The effective dose needed for AHM to protect 50% of the animals (ED<sub>50</sub>) was about 7.5 mg/kg (Figure 2). Statistical analysis showed that AHM (10-20 mg/kg) significantly increased the latency to the tonic-clonic components of PTZ-induced seizures in the unprotected mice (Table 1). At these doses, AHM significantly reduced the rate of seizures by 47 to 72% from the control, whereas the seizures rate was 100% with no protection against seizure, in the control group (Table 1).

**Effect of AHM1 on PTZ-induced convulsion**

The effects of AHM1 (5-20 mg/kg, i.p) on convulsions induced by PTZ (70 mg/kg, i.p) in mice are shown in Table 2 and Figure 3. AHM1 (5-20 mg/kg) protected 16.67-33.33% of mice against convulsions induced by PTZ (ED<sub>50</sub> of about 33.3 mg/kg) while the reference drug, clonazepam (0.1 mg/kg) offered 100% protection against
**Table 1.** Effects of AHM on the latency to the seizure and the percentage of increase of the mean seizure onset time from the control.

| Treatment      | Dose (mg/kg) | Latency to the seizure (min) [mean±SEM] |
|----------------|--------------|-----------------------------------------|
| Control (DW)   | -            | 2.57 ± 1.08                             |
| AHM            | 5            | 3.29 ± 0.86                             |
| AHM            | 10           | 4.86 ± 0.27*                            |
| AHM            | 15           | 5.48 ± 0.00**                           |
| AHM            | 20           | 9.23 ± 0.00***                          |
| Clonaz         | 1            | No convulsion                           |

Values represent the mean ± S.E.M for 6 animals per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared to control group (ANOVA followed by Dunnett’s post-hoc test).

**Figure 2.** Effects of *H. madagascariensis* crude extract on the percentage of protected mice against seizures induced by PTZ.

**Table 2.** Effects of AHM1 on the latency to the seizure induced by PTZ.

| Treatment      | Dose (mg/kg) | Latency to the seizure (min) [mean±SEM] |
|----------------|--------------|-----------------------------------------|
| Control (DW)   | -            | 2.57±1.08                               |
| AHM1           | 5            | 3.01±1.37                               |
| AHM1           | 10           | 3.90±1.04                               |
| AHM1           | 15           | 4.61±0.85*                              |
| AHM1           | 20           | 4.75±1.18*                              |
| Clonaz         | 1            | No convulsion                           |

Values represent the mean ± S.E.M for 6 animals per group. *p < 0.05 compared to control group (ANOVA followed by Dunnett’s post-hoc test).

Convulsions, as none of the animals exhibited tonic-clonic seizures induced by PTZ in mice (Figure 3).

Post-hoc test analysis by the Dunnett’s multiple comparison test showed that AHM1 (10-20 mg/kg) significantly increased the latency to the tonic-clonic components of PTZ-induced seizures in the unprotected mice (Table 2). At these doses, AHM1 significantly reduced the rate of seizures by 34 to 46%, whereas the seizures rate was 100% with no protection, in the control group (Table 2).

**Effect of AHM2 on PTZ-induced convulsion**

The effects of AHM2 (5-20 mg/kg, i.p) on convulsions induced by PTZ (70 mg/kg, i.p) in mice are shown in Table 3 and Figure 4. AHM (5-20 mg/kg) protected 50-83.33% of mice against convulsions induced by PTZ (ED50...
Figure 3. Effects of AHM1 on the percentage of protected mice against seizures induced by PTZ.

Table 3. Effect of AHM2 on the latency to the seizure induced by PTZ.

| Treatment  | Dose (mg/kg) | Latency to the seizure (min) [mean±S.E.M] |
|------------|--------------|------------------------------------------|
| Control (DW) | -            | 2.57±1.08                                |
| AHM2       | 5            | 4.31±0.69*                               |
| AHM2       | 10           | 5.74±0.46**                              |
| AHM2       | 15           | 7.12±0.00***                             |
| AHM2       | 20           | 8.53±0.00***                             |
| Clonaz     | 1            | No convulsion                            |

Values represent the mean ± S.E.M for 6 animals per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared to control group (ANOVA followed by Dunnett’s post-hoc test).

Figure 4. Effects of AHM2 on the percentage of protected mice against seizures induced by PTZ.

of about 5 mg/kg) while the reference drug, clonazepam (0.1 mg/kg) offered 100% protection against convulsions, as none of the animals exhibited tonic-clonic seizures induced by PTZ in mice (Figure 4).

Statistical analysis showed that AHM2 (5-20 mg/kg) significantly increased the latency to the tonic-clonic components of PTZ-induced seizures in the unprotected mice (Table 3). At these doses, AHM2 reduced the rate of seizures by 40 to 70%, whereas the seizures rate was 100% with no protection in the control group (Table 3).
Effect of AHM on PCT-induced convulsion

The effects of AHM (5-20 mg/kg, i.p) on convulsions induced by PCT (7.5 mg/kg, i.p) in mice are shown in Table 4 and Figure 5. AHM (5-20 mg/kg) protected 33.33-83.33% of mice against convulsions induced by PCT (ED$_{50}$ of about 11.4 mg/kg), while the reference drug, clonazepam (1 mg/kg) offered 100% protection against convulsions, as none of the animals exhibited tonic-clonic seizures induced by PCT in mice (Figure 5). Statistical analysis showed that AHM (10-20 mg/kg) significantly increased the latency to the tonic-clonic components of PCT-induced seizures in the unprotected mice. At these doses, AHM reduced the rate of seizures by 40 to 55%, whereas the seizures rate was 100% with no protection in the control group (Table 4).

Effect of AHM1 on PCT-induced convulsion

The effects of AHM1 (5-20 mg/kg, i.p) on convulsions induced by PCT (7.5 mg/kg, i.p) in mice are shown in Table 5 and Figure 6. AHM1 (5-20 mg/kg) protected
Figure 6. Effects of AHM1 on the percentage of protected mice against seizures induced by PCT.

Table 6. Effect of AHM2 on the latency to the seizure induced by PCT.

| Treatment | Dose (mg/kg) | Latency to the seizure (min) [mean±S.E.M] |
|-----------|--------------|------------------------------------------|
| Control (DW) | -            | 5.97 ± 1.35                               |
| AHM2      | 5            | 7.91 ± 14.44                              |
| AHM2      | 10           | 9.99 ± 20.08                              |
| AHM2      | 15           | 12.47 ± 26.36*                            |
| AHM2      | 20           | 13.59 ± 25.88*                            |
| Clonazepam | 0.1          | No convulsion                             |

Values represent the mean ± S.E.M for 6 animals per group. *p < 0.05, compared to control group (ANOVA followed by Dunnett’s post-hoc test).

16.67-33.33% of mice against convulsions induced by PCT (ED₅₀ of about 31.3 mg/kg) while the reference drug, clonazepam (1 mg/kg) offered 100% protection against convulsions, as none of the animals exhibited tonic-clonic seizures induced by PCT in mice (Figure 6).

Post-hoc test analysis by the Dunnett’s multiple comparison test showed that AHM1 (10-20 mg/kg) increased the latency to the tonic-clonic components of PCT-induced seizures in the unprotected mice. At these doses, AHM1 reduced the rate of seizures by 14 to 30%, whereas the seizures rate was 100% with no protection in the control group (Table 5).

Effect of AHM2 on PCT-induced convulsion

The effects of AHM2 (5-20 mg/kg, i.p) on convulsions induced by PCT (7.5 mg/kg, i.p) in mice are shown in Table 6 and Figure 7. AHM2 (5-20 mg/kg) protected 33.33-83.33% of mice against convulsions induced by PCT (ED₅₀ of about 10 mg/kg) while the reference drug, clonazepam (1 mg/kg) offered 100% protection against convulsions, as none of the animals exhibited tonic-clonic seizures induced by PCT in mice (Figure 7). Statistical analysis showed that AHM2 (10-20 mg/kg) significantly increased the latency to the tonic-clonic components of PCT-induced seizures in the unprotected mice (Table 6). At these doses, AHM2 reduced the rate of seizures by 40 to 56%, whereas the seizures rate was 100% with no protection in the control group (Table 6).

DISCUSSION

This is the first-time n-dotriacontane (AHM1) is isolated from this plant species. Friedelana-3-one (AHM2) was previously isolated from the stem bark of H. madagascariensis (Kouam et al., 2005). This is the first time it is isolated from the seeds of H. madagascariensis. However, Afieroho et al. (2012) used standard phytochemical screening reagents to reveal the presence of flavonoids aglycones, and terpenoids in the methanol extract of the seeds of H. madagascariensis.

The results of the antiepileptic assay show that AHM, AHM1 and AHM2 all provided protection against the development of seizure episodes and delayed instances of seizure induced by PTZ or PCT in mice in all their tested doses (5, 10, 15 and 20 mg/kg). At the dose of 20 mg/kg, AHM and AHM2 each considerably inhibited the action of PTZ and PCT, so much so that only 1/6 of the
animals exhibited tonic-clonic convulsions with a high latency suggesting that AHM and especially AHM2 might provide 100% like the reference drug clonazepam (1 and 0.1 mg/kg for PTZ and PCT respectively) if dose was increased to about 25 mg/kg. AHM2 could therefore possibly be the main compound responsible for the antiepileptic activity of the plant. To the best of our knowledge, this is the first report of the isolation of friedelan-3-one from the seeds of *H. madagascariensis* and also the first report of its anticonvulsant activity.

Pentylenetetrazole (PTZ) and picrotoxin (PCT) are chemoconvulsants widely used to induce convulsions in experimental animals (Umukoro et al., 2013). Seizures frequently result from an imbalance of excitation and inhibition due to a failure of inhibitory neurotransmission. The antagonism of the postsynaptic GABA A receptor leads to excessive neuronal excitation over neuronal inhibition that terminates in convulsions and death in laboratory animals (Greenfield, 2013; Annafi et al., 2014). PTZ induces convulsions by antagonizing GABA A in a competitive manner (Annafi et al., 2014). On the other hand, PCT is a non-competitive antagonist that acts through blockade of GABA A receptor chloride ion channel which is known to be resistant to most anticonvulsant agents (Umukoro et al., 2013). The fact that AHM, AHM1 and AHM2 significantly delayed the onset of seizures, and protected mice from seizures produced by both PTZ and PCT further suggests their beneficial role in curing epileptic patients or retarding the spread of seizures in epileptic brains (Annafi et al., 2014).

**Conclusion**

The anticonvulsant activity of the CH 2Cl 2/MeOH (1:1) crude extract and two compounds (n-dotriacontane and friedelan-3-one) isolated from the CH 2Cl 2/MeOH (1:1) extract of the seeds of *H. madagascariensis* (Hypericaceae) were assessed based on their abilities to prevent, or delay the onset of tonic-clonic seizures induced by PTZ and PCT in mice. The 3 treatments protected the mice at all their tested doses with the highest protection offered by friedelan-3-one followed by the crude extract and a moderate protection offered by n-dotriacontane. From these findings we suggest that n-dotriacontane and especially friedelan-3-one, could be important leads for the development of future antiepileptic drugs (AEDs). These compounds (n-dotriacontane and friedelan-3-one) have been isolated from the seeds of *H. madagascariensis* for the first time.

**CONFLICT OF INTERESTS**

The authors have not declared any conflict of interests.

**ACKNOWLEDGEMENTS**

The authors are grateful for the financial assistance through the Faculty of Science (University of Buea) 2018/2019 research grant and also the Adolphe Monkiedje Fellowship.

**REFERENCES**

Abdullahi M, Kolo I, Oyewale A, Amupitan J (2011). Antimycobacterial friedelane-terpenoid from the Root Bark of *Terminalia avicennioides*. American Journal of Chemistry 1(2):52-55.

Afieroho OE, Izentimi SS, Okorosof DO., Caleb B (2012). Antibacterial and Phytochemical Evaluation of *Harungana madagascariensis* seeds. International Research Journal of Pharmacy 3(11):75-77.

Annafi OS, Umukoro S, Edeviere AT (2014). Evaluation of the Anticonvulsant and Anxiolytic Potentials of Methyl Jasmonate in Mice. Scientia Pharmaceutica 82:643-654.

Bordoloi M, Surovi S, Prasanta KB, Bhaskor K, Partha PD, Purnajyoti DB, Subhas CD, Paruchuri GR (2017). Isolation, characterization and antifungal activity of very long chain alkane derivatives from *Cinnamomum obtusfolium, Elaeocarpus lanceolatus* and *Baccaurea sapida*. Journal of Molecular Structure 1142:200-210.

Bum EN, Schnutz M, Meyer OM, Rakotorinirina A (2001). Anticonvulsant Properties of the Methanolic Extract of *Cyperus articulatus* (Cyperaceae). Journal of Ethnopharmacology 76(2):145-150.
Bum EN, Soudi S, Ayissi ER, Dong C, Laloulo NH, Maidawa F, Seke PFE, Nanga LD, Taiwe GS, Dimo T, Njifutie N, Rakotonirina A, Rakotonirina SV, Kamanyi A (2011). Anxiety Activity Evaluation of Four Medicinal Plants from Cameroon. African Journal of Traditional, Complementary and Alternative Medicine 8(5):130-139.

Greenfield LJ (2013). Molecular Mechanisms of Antiseizure Drug Activity at GABA Receptors. Seizure 22(8):589-600.

Hui-Ling Z, Jian-Bo W, Yi-Tao W, Bao-Cai L, Cheng X, Jing H., Peng L (2014). Medicinal Compounds with antiepileptic/anticonvulsant Activities. Journal of Epilepsia 55(1):3-16.

Kouam SF, Ngadjui BT, Krohn K, Wafo P, Ajaz A, Choudhary MI (2005). Prenylatedanthronoid antioxidants from the stem bark of Harungana madagascariensis. Phytochemistry 66:1174-1179.

Kouam SF, Yapna DB, Krohn K, Ngadjui BT, Ngoupayo J, Choudhary MI, Schulz B (2007). Antimicrobial prenylated anthracene derivatives from the leaves of Harungana madagascariensis. Journal of Natural Products 70(1):600-603.

Lenta BN, Ngouela S, Boyom FF, Tantangmo F, Tchouya GRF, Tsamo E, Gut J, Rosenthal PJ, Connolly JD (2007). Anti-plasmodial activity of some constituents of the root bark of Harungana madagascariensis LAM. (Hypericaceae). Chemical and Pharmaceutical Bulletin 55(1):464-467.

Nirupam D, Meenakshi D, Sushant KS (2012). An Overview on Antiepileptic Drugs. Journal of Drug Discovery and Therapeutics 6(4):178-193.

Noumi E, Fozi FL (2003). Ethnomedical Botany of Epilepsy Treatment in Fongo-Tongo Village, Western Province, Cameroon. Journal of Pharmaceutical Biology 41(5):330-339.

Umukoro S, Itivere AO, Anthony TE (2013). Evaluation of the Effect of Jobelyn on Chemoconvulsants Induced Seizure in Mice. Journal of Basic and Clinical Neuroscience 4(2):19-23.

Wagner RG (2016). The Burden of Epilepsy Using population-based data to define the Burden and Model a Cost-effective Intervention for the Treatment of Epilepsy in Rural South Africa. Print and Media Umeå, Sweden, pp. 1-7.

Wahab A (2010). Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development. Journal of Pharmaceuticals 3:2091-2110.

Wahab OM (2015). Ethnomedicinal Antiepileptic Plants Used in Parts of Oyo and Osun States, Nigeria. Journal of Botany Research International 8(4):77-81.